Insilico reports positive early human trial results for mesothelioma drug
Insilico Medicine presented first-in-human Phase 1 data for ISM6331 at the European Society for Medical Oncology Congress 2026. Among response-evaluable mesothelioma participants, the company reported a 40.0% objective response rate at 130 mg once daily (two of five evaluable) and an 18.2% ORR overa
<p>Insilico Medicine presented first-in-human Phase 1 data for ISM6331 at the European Society for Medical Oncology Congress 2026. Among response-evaluable mesothelioma participants, the company reported a 40.0% objective response rate at 130 mg once daily (two of five evaluable) and an 18.2% ORR overa</p>